

THE FIRST GLOBAL SPASTICITY SYMPOSIUM

Final Program

SPASTICITY

OCTOBER 24-26, 2024

Houston Texas, USA | The Westin Galleria



A Meeting of the Minds to X-out Spasticity

Spasticity X is the First International Spasticity Symposium bringing together top experts and rising stars in spasticity and sensorimotor disorders from around the globe.

WHAT TO EXPECT

Attendees can expect everything from didactic lectures, small group discussions, and poster presentations, to hands-on workshops and networking events.

BROUGHT TO YOU BY...

Spasticity X is a collaboration of the Association of Academic Physiatrists (AAP), the International Society for Physical and Rehabilitation Medicine (ISPRM), and TIRR Memorial Hermann.



Association of Academic Physiatrists




GET SOCIAL

Take to social media to hear from speakers and presenters, exchange diverse insights and opinions, and stay on top of the event's latest news using **#SpasticityX**, our official event hashtag.

STAY UPDATED WITH OUR EVENT APP

Be sure to download our event app to stay up-to-date on event descriptions and timelines and connect with other attendees.



scan the QR code to
download the app

MERZ THERAPEUTICS

IS PROUD TO BE A SPONSOR
OF **SPASTICITY X**

Everything we do is
in relentless pursuit of
better outcomes for more
patients.

Visit MerzTherapeutics.com/US to learn more



THERAPEUTICS

Better outcomes for more patients.

VISIT US
IN THE
**EXHIBIT
HALL**

Copyright © 2024 Merz Pharmaceuticals, LLC. All rights reserved. Merz and the Merz logo are registered trademarks of Merz Pharma GmbH & Co. KGaA. Merz Therapeutics is a business of Merz Pharmaceuticals, LLC.

US-XET-2400082

WELCOME TO SPASTICITY X, y'all! I can barely contain my excitement to personally welcome all from near and far to my beloved hometown, Houston.

Spasticity X is bringing together over 300 of the leading minds and up & coming stars in spasticity from around the world for three jam-packed days of learning, collaborating, networking, brainstorming, and more. We will also have 60 posters being presented during our Poster Gallery event on Thursday evening (enjoy a glass of wine and Q&A with the authors!)



Our *Spasticity X* cohort hails from 35 countries – everywhere from Australia to Brazil, from Cameroon to Italy, from Myanmar to the Philippines, and many others. We know that we are stronger together and encourage everyone to bring their unique perspectives and expertise to each session, networking event, and the Expo Hall.

Make sure you carve out some time for fun and networking at various events hosted by our sponsors who are the leaders in the industry and excellent partners in improving the lives of our patients. *Spasticity X* would simply not be possible without our sponsors and exhibitors.

Be sure to join us for our **Texas Hoedown!**,* which will have a country-and-western theme. Throw on your favorite pair of jeans, cowboy hats, and boots! There will be Texas barbecue, lively music, and line dancing. If you have no idea what line dancing and hoedown are, do not worry; there will be a dance instructor at the event!

Proceedings of *Spasticity X* will be published as an e-book, which we look forward to sharing with each of you.

A highlight of *Spasticity X* is the presentation of the output of the work by the *Spasticity Redefinition Workgroup*. Members of this workgroup are already preparing for the in-person meeting, the expected remit of which is to recommend a new definition of spasticity (or endorse an existing one). Another highlight will be a couple of announcements I will make during my presentation on Saturday afternoon (“Spasticity 2030”). One will be about the next Spasticity X meeting, and the other, well, it will be a surprise.

I want to thank you all once again for accepting my invitation to be part of *Spasticity X: The First International Spasticity Symposium*. I hope that this meeting will strengthen current collaborations and foster the creation of new relationships grounded in our common interest in advancing the science and practice of spasticity.

See y'all soon!

A handwritten signature in blue ink that reads "Gerard Francisco MD". The signature is stylized and fluid.

Gerard Francisco, MD
Chair, *Spasticity X* Steering Committee

Ipsen Biopharmaceuticals Lunch and Learn

Join us on **Friday, October 25th**,
for an engaging session

SESSION IS **FREE** AND DOES NOT REQUIRE PRE-REGISTRATION

Live Patient Case and Toxin Injection

with Dr Monica Verduzco-Gutierrez

Friday, October 25th

12:30 PM - 1:30 PM



Spasticity X 2024
Houston, TX



Come visit us
at booth 202



- Presentation is a Dysport (abobotulinumtoxinA) promotional program provided by Ipsen Biopharmaceuticals, Inc.
- Presenter is speaking on behalf of Ipsen and is being compensated for their time
- Presentation is not a continuing medical education (CME) program

INDICATIONS

DYSPORT (abobotulinumtoxinA) for injection is indicated for the treatment of:

- spasticity in patients 2 years of age and older
- cervical dystonia in adults

IMPORTANT SAFETY INFORMATION

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of DYSPORT and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.

Please see additional Important Safety Information on the next page and accompanying full Prescribing Information, including **BOXED WARNING**.

IMPORTANT SAFETY INFORMATION (continued)

Contraindications

DYSPORT is contraindicated in patients with known hypersensitivity to any botulinum toxin products, cow's milk protein, or to any of the components in the formulation, or infection at the proposed injection site(s). Serious hypersensitivity reactions including anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea have been reported. If such a serious reaction occurs, discontinue DYSPORT and institute appropriate medical therapy immediately.

Warnings and Precautions

Lack of Interchangeability Between Botulinum Toxin Products

The potency Units of DYSPORT are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of DYSPORT cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

Dysphagia and Breathing Difficulties

Treatment with DYSPORT and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several weeks and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. Treatment of cervical dystonia with botulinum toxins may weaken accessory muscles of ventilation, which may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these muscles. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.

Pre-existing Neuromuscular Disorders

Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junction disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of DYSPORT.

Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, vCJD, or CJD have ever been identified for licensed albumin or albumin contained in other licensed products.

Intradermal Immune Reaction

The possibility of an immune reaction when injected intradermally is unknown. The safety of DYSPORT for the treatment of hyperhidrosis has not been established. DYSPORT is approved only for intramuscular injection.

Pre-existing Conditions at the Injection Site

Caution should be exercised when DYSPORT is used where the targeted muscle shows excessive weakness or atrophy.

Adverse Reactions

- The most common adverse reactions ($\geq 4\%$) in adults with upper limb spasticity include muscular weakness; in adults with lower limb spasticity ($\geq 5\%$) include falls, muscular weakness, and pain in extremity
- The most common adverse reactions ($\geq 10\%$) in pediatric patients with upper limb spasticity include upper respiratory tract infection and pharyngitis; in pediatric patients with lower limb spasticity include nasopharyngitis, cough, and pyrexia
- The most common adverse reactions ($\geq 5\%$) in adults with cervical dystonia include muscular weakness, dysphagia, dry mouth, injection site discomfort, fatigue, headache, musculoskeletal pain, dysphonia, injection site pain, and eye disorders

Drug Interactions

Co-administration of DYSPORT and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents) should only be performed with caution because the effect of the botulinum toxin may be potentiated. Use of anticholinergic drugs after administration of DYSPORT may potentiate systemic anticholinergic effects such as blurred vision. The effect of administering different botulinum neurotoxins at the same time or within several months of each other is unknown. Excessive weakness may be exacerbated by another administration of botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before and after administration of DYSPORT.

Please see accompanying full Prescribing Information, including BOXED WARNING.



Dysport is a registered trademark of Ipsen Biopharm Limited.

©2024 Ipsen Biopharmaceuticals, Inc. Printed in USA October 2024 DYS-US-009098



WELCOME TO HOUSTON!



The “City With No Limits” is the fourth most populous city in the US. It’s a fast-growing metropolis due to thriving medicine, engineering, oil, gas and aeronautic industries, and is closely linked with the Space Center Houston, the coastal visitor center at NASA’s astronaut training and flight control complex.

The city’s relatively compact Downtown includes the Theater District, home to the renowned Houston Grand Opera, and the Historic District, with 19th-century architecture and upscale restaurants.

Houston is home to the largest medical facility in the world, the Texas Medical Center, and with over 145 languages spoken, it has married traditional southern charm with educational and cultural excellence.

THINGS TO DO



✈️ **AIRPORT: GEORGE BUSH INTERCONTINENTAL AIRPORT (IAH)**

💵 **CURRENCY: \$ USD**

🕒 **TIME ZONE: CENTRAL DAYLIGHT TIME (CST)**



SCHEDULE AT-A-GLANCE

Wednesday, October 23, 2024

1:00-5:00PM:

Cryoneurolysis Lab: Novel & Emerging Treatment for Pain Associated with Spasticity



Thursday, October 24, 2024

1:30-1:50PM:

Welcome: Official Start of Spasticity X

1:50-2:15PM:

KEYNOTE 1: Milestones in the 40 years Since Lance Defined Spasticity

2:15-2:40PM:

KEYNOTE 2: What is Spasticity? Revisiting the Pathophysiology of Spasticity

2:40-3:05PM:

KEYNOTE 3: Spasticity and Pain

3:05-3:20PM:

Q&A

4:00-5:30PM:

Parallel Sessions:

- Session 1: Pathophysiology
- Session 2: Special Topics, Part 1

5:30-7:00PM:

Welcome & Poster Gallery Reception



Friday, October 25, 2024

7:00-8:00AM:

Breakfast Symposium: Changing the tone: Addressing Inequities in Spasticity Care, *supported by AbbVie*

8:00-10:00AM:

Parallel Sessions:

- Session 3: Spotlight on Emerging Experts
- Session 4: Imaging and Operant Conditioning

10:00-10:45AM:

Hands-On Demo: ITB Pump Refill, *supported by Piramal*

10:30am-12:15pm:

Parallel Sessions:

- Session 5: Physical Interventions
- Session 6: The Lived Experience of Spasticity

12:30-1:30PM:

Lunch & Learn Product Theater: Live Patient Case & Toxin Injection, *supported by Ipsen*

1:40-3:15PM:

Parallel Sessions:

- Session 7: Advanced Technology Applications in Spasticity
- Session 8: Special Topics, Part 2

3:15-4:00PM:

Pump the Brakes: Enhancing Sterility and Efficiency of Intrathecal Baclofen Pump Refills, *supported by Amneal*

3:45-5:40PM:

Parallel Sessions:

- Session 9: Journal Club, sponsored by the UTHealth McGovern Medical School Department of PM&R
- Session 10: Focus on Neurolysis

5:30-6:30PM:

Happy Hour in Expo Hall

6:30-8:00PM:

Texas Hoedown Networking Night

Saturday, October 26, 2024

8:00-8:25AM:

Educational Sessions

8:25-8:50AM:

KEYNOTE 4: Clinical Research for spasticity: Challenges and Opportunities

8:50-9:15AM:

KEYNOTE 5: How the Muscle Extracellular Matrix Contributes to Spasticity, Stiffness, Abnormal Synergies and Pain

9:15-9:25AM:

Q&A: Session Chairs

9:25-10:00AM:

Breakfast in the Expo Hall

10:00-11:15AM:

Educational Sessions

11:15-11:30AM:

Q&A: Session Chairs

11:30AM-12:10PM:

Educational Sessions

12:10-12:30PM:

Q&A: Session Chairs

12:30-1:30PM:

Lunch & Learn Symposium, *supported by Merz*

1:40-3:40PM:

Educational Sessions

3:40-4:10:

BREAK

4:10-5:05PM:

Educational Sessions

5:05-5:15PM:

Closing Remarks and Adjournment

Be sure to download the event app to get details on sessions, build your schedule, and get the latest updates.





NO ROOM FOR ERROR

The updated Lioresal® Intrathecal (baclofen injection) refill kit with the first and only 100% sterile presentation on the market¹



The redesigned Lioresal® refill kit is built for efficiency, with:



- a presentation that follows the flow of clinical process to ensure consistency and predictability from refill to refill



- more than a dozen enhancements based on feedback from healthcare professionals like you* including a Quick Reference Guide, additional sterile drape, and a new sharps holder

*Based on feedback from healthcare professionals who manage IT baclofen pumps.

Important Safety Information for ITB Therapy with Lioresal® Intrathecal (baclofen injection)

Indications and Usage

Lioresal® Intrathecal (baclofen injection) is a muscle relaxant and antispastic that is indicated for use in the management of severe spasticity of cerebral or spinal origin. Lioresal® Intrathecal is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only in implantable pumps approved by the FDA specifically for the administration of Lioresal® Intrathecal into the intrathecal space. Lioresal® Intrathecal via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. Prior to implantation of a device for chronic intrathecal infusion of Lioresal® Intrathecal, patients must show a response to Lioresal® Intrathecal in a screening trial. Please review the dosing and administration section of the Lioresal® Intrathecal prescribing information for further details.

Abrupt discontinuation of intrathecal baclofen, regardless of the cause, has resulted in sequelae that include high fever, altered mental status, exaggerated rebound spasticity, and muscle rigidity, that in rare cases has advanced to rhabdomyolysis, multiple organ-system failure and death. Prevention of abrupt discontinuation of intrathecal baclofen requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms. Patients and caregivers should be advised of the importance of keeping scheduled refill visits and should be educated on the early symptoms of baclofen withdrawal. Special attention should be given to patients at apparent risk (e.g., spinal cord injuries at T-6 or above, communication difficulties, history of withdrawal symptoms from oral or intrathecal baclofen). Consult the technical manual of the implantable infusion system for additional postimplant clinician and patient information.

Please visit www.LIORESAL.com for full prescribing Information.

References: 1. Saol Therapeutics Inc. Data on file: NDA 020075 Lioresal; 3.2.P.8 Stability and 3.2.P.8.2 Post-Approval Stability Protocol and Stability Commitment.



Lioresal is a registered trademark of Amneal Pharmaceuticals LLC.
©2024 Amneal Pharmaceuticals LLC. All Rights Reserved.
PP-CVA-LIORE-US-0004



Join us for our Signature Events:

There is no fee to attend, registration is not required, and seating is available on a first-come, first-serve basis

THURSDAY, OCTOBER 24, 2024

5:30PM – 7:00PM (Galleria Foyer)

Welcome & Poster Gallery Reception

FRIDAY, OCTOBER 25, 2024

7:00AM – 8:00AM (Plaza)

Hot Breakfast Symposium: Changing the Tone:
Addressing Inequities in Spasticity Care

SUPPORTED BY 

10:00AM – 10:45AM (Expo Hall)

Demo Pod: Hands-On ITB Pump Refill Demos

SUPPORTED BY 

12:30PM – 1:30PM (Plaza)

Lunch & Learn: Live Patient Care & Toxin Injection

SUPPORTED BY 

3:15PM – 4:00PM (Expo Hall)

Demo Pod: Pump the Brakes: Enhancing Sterility and
Efficiency of Intrathecal Baclofen Pump Refills

SUPPORTED BY 

5:30PM – 6:30PM

Happy Hour in Expo Hall

6:30PM – 8:00PM (Monarch Room)

Texas Hoedown

SUPPORTED BY 

SATURDAY, OCTOBER 26, 2024

9:25AM – 10:00AM

Breakfast in Expo Hall

12:30PM – 1:30PM (Plaza)

Lunch & Learn: Leveraging Ultrasound to Plan Injection
Approaches for Upper Limb Spasticity

SUPPORTED BY 
THERAPEUTICS

SPASTICITY

YOU'RE INVITED TO OUR

Texas Hoedown!



FRIDAY, OCTOBER 25 | 6:30-8:00PM

The Westin Galleria Houston – Monarch Room

Get ready to experience the heart and soul of Texas at our unforgettable Texas Hoedown! Come for the cocktails, Texas BBQ, and lively music to show off your best line-dancing moves. Feel free to dress in your best casual country western attire!

SCAN THE
QR CODE TO
REGISTER



SUPPORTED BY:



The Gablofen® Difference

The only FDA-approved
Intrathecal Baclofen packaged
in prefilled syringes and
factory-sealed vials.

CONVENIENCE

- Prefilled syringes eliminates the need to draw, measure or dilute - 500 mcg/mL, 1000 mcg/mL and 2000 mcg/mL*
- Factory-sealed vials eliminates need to break ampules, requires no dilution and reduces waste - 500 mcg/mL, 1000 mcg/mL and 2000 mcg/mL*

CLINICIAN SUPPORT

- Clinician training and ongoing education to support use accuracy
- On-site support increases injection confidence and comfort

Learn more at [Gablofen.com](https://gablofen.com) today.

Visit Us at Booth #102!

FASTER REFILLS

- Three concentration choices help optimize refill times
- Reduced number of steps enables faster refill prep

COMPATIBILITY

- FDA-approved for up to 180 days of use in the Medtronic SynchroMed Programmable Pump*



Gablofen®
(baclofen injection)

*Gablofen [IUSPI], Bethlehem, PA: Piramal Critical Care, Inc.; Sept. 2024.

MKT-GAB-0246

SPASTICITY EXHIBITOR GUIDE

VISIT THESE EXHIBITORS IN THE EXPO HALL

AbbVie | IRVINE, CALIFORNIA | BOOTHS 104 & 303

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Amneal Pharmaceuticals | BRIDGEWATER, NEW JERSEY | BOOTH 304

At Amneal, we believe in reducing barriers to patients accessing the medicines they need most. In fact, Amneal's founding 20-years ago was catalyzed by the desire to do something about the heartbreaking decision pharmacy patients were making between food and their essential medicines. That desire is amplified today with our broadening portfolio of quality products, including biosimilars – which we believe represent the future of accessibility to some of the most sophisticated therapies ever developed.

Ipsen Biopharmaceuticals | CAMBRIDGE, MASSACHUSETTS | BOOTHS 100 & 202

Ipsen Biopharmaceuticals, Inc. is the U.S. affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical group focused on innovation and specialty care. The company is dedicated to providing hope for patients whose lives are challenged by difficult-to-treat diseases, focusing its resources, investments and energy on discovering, developing and commercializing new therapeutic options in oncology, neurosciences and rare diseases.

Medtronic | MINNEAPOLIS, MINNESOTA | BOOTH 302

As a global leader in medical technology, services and solutions, Medtronic improves the lives and health of millions of people each year. We use our clinical, therapeutic, and economic expertise to address the complex challenges faced by healthcare systems. Let's take healthcare Further, Together. Learn more at Medtronic.com.

Merz Therapeutics | RALEIGH, NORTH CAROLINA | BOOTH 200 & 300

At Merz Therapeutics, we seek to address the unique needs of people who suffer from movement disorders, neurological conditions, and other health conditions that severely impact patients' quality of life. With our patient-centric approach, cutting-edge research and development efforts, highly-scientific medical affairs resources and dedicated commercial teams, we continue the advancement of new and individualized treatment standards, including botulinum toxin.

Piramal Critical Care | BETHLEHEM, PENNSYLVANIA | BOOTH 102

With nearly 20 years in the healthcare industry, Piramal Critical Care, (PCC) is committed to delivering critical care solutions to patients and healthcare providers worldwide. PCC is leading the way in intrathecal medicine with offerings for pain and spasticity management while representing a culture built on collaboration, innovation, and service.

TIRR Memorial Hermann | HOUSTON, TEXAS | BOOTH 305

Continually recognized as one of America's Best Hospitals, TIRR Memorial Hermann is a national leader in medical rehabilitation and research.

Special thank you to the Spasticity X Steering Committee and Scientific Advisory Committee for selfishly lending their time, energy, and expertise to develop this truly unique & remarkable program:

SCIENTIFIC STEERING COMMITTEE

Prof. Alberto Esquenazi (ELKINS PARK, USA)

Prof. Gerard Francisco (HOUSTON, USA), chair

Prof. Sheng Li (HOUSTON, USA)

Prof. Areerat Suputtitada (BANGKOK, THAILAND)

Prof. Jörg Wissel (BERLIN, GERMANY)

SCIENTIFIC ADVISORY COMMITTEE

Dr. Abdulla Alrahoomi (ABU DHABI, UAE)

Prof. Marta Banach (KRAKÓW, POLAND)

Prof. Ryuji Kaji (TOKYO, JAPAN)

Dr. Patricia Khan (FLORIANOPOLIS, BRAZIL)

Dr. Maud Pradines (Paris, France)

Prof. Rajiv Reebye (VANCOUVER, CANADA)

Prof. Raymond Rosales (MANILA, PHILIPPINES)

Dr. Fabienne Schillebeeckx (LEUVEN, BELGIUM)

Prof. Lynne Turner-Stokes (LONDON, UK)

Dr. Michael Temgoua (YAOUNDÉ, CAMEROON)

Thank you to our Sponsors for their generous support!



abbvie

